This document is an excerpt from the EUR-Lex website
Document 62021TN0695
Case T-695/21: Action brought on 28 October 2021 — Alauzun and Others v Commission
Case T-695/21: Action brought on 28 October 2021 — Alauzun and Others v Commission
Case T-695/21: Action brought on 28 October 2021 — Alauzun and Others v Commission
OJ C 2, 3.1.2022, p. 45–45
(BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
3.1.2022 |
EN |
Official Journal of the European Union |
C 2/45 |
Action brought on 28 October 2021 — Alauzun and Others v Commission
(Case T-695/21)
(2022/C 2/62)
Language of the case: French
Parties
Applicants: Virginie Alauzun (Saint Cannat, France) and 774 other applicants (represented by: F. Di Vizio, lawyer)
Defendant: European Commission
Form of order sought
The applicants claim that the Court should:
— |
declare that the European Commission (EC) unlawfully failed to include carcinogenicity and genotoxicity testing in the preclinical phase for the mRNA-technology vaccines; |
— |
order the European Commission to include carcinogenicity and genotoxicity testing in the preclinical phase for mRNA-technology vaccines not yet authorised under the EMA procedure; |
— |
order the European Commission to include carcinogenicity and genotoxicity testing in the pharmacovigilance phase for mRNA-technology vaccines already authorised under the EMA procedure; |
— |
request the Commission to disclose the following information:
|
— |
order the European Commission to pay all the costs of the applicants. |
Pleas in law and main arguments
In support of the action, the applicants allege an infringement of EU law and a failure to act on the part of the Commission. The applicants submit in that regard that the Commission did not comply with its obligation arising under Article 168 TFEU to guarantee a ‘high level of human health protection’ by granting a conditional marketing authorisation to mRNA-technology vaccines in the absence of carcinogenicity and genotoxicity studies.